Lead Product(s): MOR210,Undisclosed
Therapeutic Area: Oncology Product Name: TJ210
Highest Development Status: IND Enabling Product Type: Large molecule
Partner/Sponsor/Collaborator: I-Mab Biopharma
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable September 17, 2020
MOR210/TJ210 is a highly differentiated monoclonal antibody that is directed against complement factor C5a receptor 1 (C5aR1). The phase 1 clinical trial, designed to evaluate the safety, tolerability, pharmacokinetics and pharmacodynamics of MOR210/TJ210.